Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +3.70%26 Debt-to-EBITDA is 1.46 as of Jun. 2026, which is 54% below its 10-year median of 3.14. GuruFocus rates ROCO:7762 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 676 Drug Manufacturers companies, Pet Pharm Biotech Co ranks better than 53.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pet Pharm Biotech Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:7762'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.42 Med: 3.14 Max: 4.71
Current: 1.42
During the past 4 years, the highest Debt-to-EBITDA Ratio of Pet Pharm Biotech Co was 4.71. The lowest was 1.42. And the median was 3.14.
ROCO:7762's Debt-to-EBITDA is ranked better than 53.55% of 676
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs ROCO:7762: 1.42
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pet Pharm Biotech Co Debt-to-EBITDA Related Terms
Pet Pharm Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Pet Pharm Biotech Co (ROCO:7762) has a Debt-to-EBITDA of 1.46 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pet Pharm Biotech Co. This is 54% below median its historical median of 3.14. Over the past decade, Pet Pharm Biotech Co's Debt-to-EBITDA has ranged from 1.42 to 4.71. According to the industry distribution chart, Pet Pharm Biotech Co ranks #314 out of 676 companies in the Drug Manufacturers industry, placing it in the top 46.4%.
Is Pet Pharm Biotech Co's Debt-to-EBITDA too high?
Pet Pharm Biotech Co's current Debt-to-EBITDA of 1.46 is 54% below median its 10-year median of 3.14. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 4.71. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Pet Pharm Biotech Co's value of 1.46 is 11% below this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #314 out of 676 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #314 out of 676 companies for Debt-to-EBITDA. This puts Pet Pharm Biotech Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Pet Pharm Biotech Co's value of 1.46 is 11% below this benchmark. Historically, Pet Pharm Biotech Co's own Debt-to-EBITDA has ranged from 1.42 to 4.71 over the past decade. While the company's 10-year median is 3.14 vs. the industry median of 1.64, Pet Pharm Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current Debt-to-EBITDA of 1.46 is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pet Pharm Biotech Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current Debt-to-EBITDA is 1.46, which is 54% below median its own 10-year median of 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Debt-to-EBITDA of 1.46. The current Debt-to-EBITDA is 1.46, which is 54% below median its 10-year median of 3.14 and 11% below the Drug Manufacturers industry median of 1.64. Pet Pharm Biotech Co's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Debt-to-EBITDA is 1.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
26GF Score
Get the complete analysis for ROCO:7762
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
